Yuji Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuji Sato has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bailong Sun
Department of General Surgery, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
1 shared publication - Hiroaki Nakagawa
Graduate School of Advanced Life Science, Hokkaido University, Sapporo 001-0021, 001-0021, Japan
1 shared publication - Jun Hamaguchi
Department of General Surgery, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
1 shared publication - Kisaburo Deguchi
Graduate School of Advanced Life Science, Hokkaido University, Sapporo 001-0021, Japan
1 shared publication - Masato Takahashi
National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
1 shared publication - Naoya Kamiyama
Department of Sensory Physiology, Asahikawa Medical College, Asahikawa 078-8510, Japan
1 shared publication
Latest Publications
- Open Access
- 21 September 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 58
Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines
Background: Drug resistance is a major problem in cancer chemotherapy. Acquisition of chemo-resistance not only reduces the effectiveness of drugs, but also promotes side effects and markedly reduces the patient's quality of life. However, a number of resistance mechanisms have been reported and are thought to be the reason for the difficulties in solving drug-resistance problems. Result: To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line. The expression of thymidylate synthase, orotic acid phosphoribosyltransferase and dihydropyrimidine dehydrogenase, which are well known to be related to drug resistance, differed among these cell lines, indicating that these cell lines acquired different resistance mechanisms. However, swainsonine, an inhibitor of N-glycan biosynthesis, reduced 5-FU-tolerance in all resistant cells, whereas the sensitivity of the parental cells was unchanged. Further analysis of the N-glycan profiles of all cell lines showed partial inhibition of biosynthesis and no cytotoxicity at the swainsonine dosage tested. Conclusion: These observations suggest that N-linked oligosaccharides affect 5-FU resistance more widely than do drug-resistance related enzymes in colorectal cancer cells, and that the N-glycan could be a universal target for chemotherapy. Further, swainsonine may enhance the performance of chemotherapy by reducing tolerance.
- 21 September 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 58
Open AccessSwainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines
Background: Drug resistance is a major problem in cancer chemotherapy. Acquisition of chemo-resistance not only reduces the effectiveness of drugs, but also promotes side effects and markedly reduces the patient's quality of life. However, a number of resistance mechanisms have been reported and are thought to be the reason for the difficulties in solving drug-resistance problems. Result: To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line. The expression of thymidylate synthase, orotic acid phosphoribosyltransferase and dihydropyrimidine dehydrogenase, which are well known to be related to drug resistance, differed among these cell lines, indicating that these cell lines acquired different resistance mechanisms. However, swainsonine, an inhibitor of N-glycan biosynthesis, reduced 5-FU-tolerance in all resistant cells, whereas the sensitivity of the parental cells was unchanged. Further analysis of the N-glycan profiles of all cell lines showed partial inhibition of biosynthesis and no cytotoxicity at the swainsonine dosage tested. Conclusion: These observations suggest that N-linked oligosaccharides affect 5-FU resistance more widely than do drug-resistance related enzymes in colorectal cancer cells, and that the N-glycan could be a universal target for chemotherapy. Further, swainsonine may enhance the performance of chemotherapy by reducing tolerance.